In addition to the uncertainty about the spectrum of cancers associated with BRCA2, the reported penetrance for each cancer type in carriers varies considerably, ranging from 30% to 80% for breast cancer, 13%–29% for ovarian cancer, 5%–10% for pancreatic cancer, and 19%–61% for prostate cancer [13, 14, 15, 16, 17]. This evidence concerns the gene BRCA2 and breast cancer.